Gastric variceal bleeding is associated with significant morbidity and mortality in patients with portal hypertension and cirrhosis. Options are limited for patients who are not candidates for transjugular intrahepatic portosystemic shunts (TIPS). Cyanoacrylate injections have been reported to be efficacious in previous case series. The aim of this retrospective study was to report our single-center experience with the safety and efficacy of 2-octyl-cyanoacrylate in patients who were not TIPS candidates. Electronic medical records were reviewed for 16 patients who underwent a total of 18 esophagogastroduodenoscopies for acute gastric or duodenal variceal bleeding and secondary prophylaxis of gastric varices; 14 patients had cirrhosis with an average Model for End-Stage Liver Disease score of 16, and 2 patients had noncirrhotic portal hypertension. Primary endpoints of the study included early and delayed rebleeding rate, complications, and death or liver transplantation. The rebleeding rate (early or delayed) was 7%, and no complications were found. One death was reported (unrelated to the procedure). In conclusion, 2-octylcyanoacrylate is a safe and effective alternative for non-TIPS candidates who present with acute gastric variceal bleeding given its low rebleeding and complication rate. I n general, management of acute gastric variceal bleeding consists of a combination of pharmacological therapy (octreotide bolus, followed by infusion), endoscopic therapy (banding ligation in the case of gastroesophageal varices type 1), bridge therapy (balloon tamponade), and rescue therapy (transjugular intrahepatic portosystemic shunts [TIPS]) in cases of high risk of rebleed or refractory bleeding. However, patients with severe decompensation of liver disease or signifi cant thrombus of hepatic vasculature are not ideal candidates for TIPS or balloon-occluded retrograde transvenous obliteration ( 1, 2 ), therefore limiting their therapeutic options to the use of tissue glues. 2-Octyl-cyanoacrylate is a monomer that rapidly polymerizes when it comes into contact with weak bases (blood and water). Several trials have demonstrated a similar hemostasis rate compared with alcohol and ethanolamine, a lower rate of rebleeding compared with band ligation, and a reduced rebleeding rate compared with beta-blockers ( 3-5 ). However, most studies of cyanoacrylate have been performed outside of the United States, mainly in Asia and Europe. Th e purpose of our study was to report our experience with 2-octyl-cyanoacrylate in From the Divisions of Gastroenterology (Lizardo-Sanchez, Burdick) and Hepatology
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METHODS
Th is was a retrospective analysis of 16 patients who presented to our institution with gastric or duodenal variceal bleeding with high-risk stigmata (defi ned as nipple sign, red wale sign, or size >10 mm). Most patients had decompensated cirrhosis and were not candidates for TIPS. Patients were treated with 2-octyl-cyanoacrylate between July 2012 and October 2014 for active bleeding or secondary prophylaxis of bleeding. Th e study was approved by the Baylor University Medical Center institutional review board. After explaining risks, benefi ts, and alternatives of the procedure, we obtained informed consent from patients, or family members if the patient could not provide consent, prior to each procedure.
Patients' deidentifi ed data were obtained through review of electronic medical records. Th e information obtained included age, gender, liver disease (i.e., cirrhosis or portal vein thrombus), TIPS candidacy, esophagogastroduodenoscopy reports, progress notes, laboratory data for Model for End-Stage Liver Disease (MELD) score calculation (complete blood count, comprehensive metabolic panel, prothrombin time), and details regarding administration of cyanoacrylate (milliliters administered, number of sessions). Varices were classifi ed according to location (gastric or duodenal). Th e Sarin anatomic classifi cation system was used to characterize gastric varices. Dates were noted for death, liver transplantation, or last clinic or hospital follow-up.
Patients with gastric or duodenal varices underwent endoscopy for active bleeding or secondary prophylaxis in the hospital setting ( Figure ) . Two experienced endoscopists (JB, JT) administered the 2-octyl-cyanoacrylate with anesthesia assistance. Olympus GF 160 and 180 therapeutic endoscopes were utilized. Marcon-Haber metallic injector sclerotherapy Baylor University Medical Center Proceedings Volume 29, Number 4 needles (Cook-Medical, Winston-Salem, NC) were used for procedures. All patients received 2-octyl-cyanoacrylate for variceal obliteration. Th e varices were targeted both in a forward view and retrofl ex fashion, depending on endoscopic preference and varix angle. Th e rate of cyanoacrylate administered was 1 to 2 mL/minute. Th e amount and sessions of glue injections varied according to endoscopists' assessment of variceal obliteration and clinical evidence of active bleeding. Th e study had four primary endpoints: • Early rebleeding rate, defi ned as percentage of patients with evidence of overt gastrointestinal bleeding 7 days after the procedure • Delayed rebleeding rate, defi ned as percentage of patients with evidence of overt bleeding 8 to 90 days after the procedure • Complications, including pulmonary embolism, stroke, perforation, infection, or failure to achieve hemostasis requiring urgent TIPS • Death from any cause
RESULTS
During the study period of July 2012 to February 2014, 16 patients were identifi ed who underwent a total of 18 esophagogastroduodenoscopies with cyanoacrylate injection. Fourteen of the 16 patients had cirrhosis, with predominant etiologies including cryptogenic, chronic hepatitis C, and alcoholic liver disease ( Table ) . Two patients had noncirrhotic portal hypertension associated with portal vein thrombosis.
Most patients (78%) underwent cyanoacrylate injection for active gastrointestinal bleeding; 22% who underwent this procedure were referred for secondary prophylaxis after experiencing an episode of gastric variceal bleeding. Based on Sarin's classifi cation, most varices were classifi ed as GOV-2 (50%), followed by IGV-1 (38%) and duodenal varices (19%). Th e average MELD score was 16 (standard deviation [SD], 9).
A total of 18 procedures were performed on 16 patients. Th e mean number of injections was 1.5. Th e median amount of the injection used for the procedure was 4.2 mL (SD, 1.3 mL). Immediate postprocedure hemostasis was accomplished in 93% of patients who presented with acute gastric variceal bleeding ( Table ) .
Th e median follow-up for our patients was 461 days (SD, 224 days). Among the patients who presented with active bleeding, one experienced early rebleeding at day 2 and another was found to have delayed rebleeding at day 9. Although one of these patients was not deemed to be an ideal candidate for TIPS placement, he was able to undergo this procedure as a salvage therapy. One technical complication was reported due to catheter malfunction (glue not deployed), but no pulmonary embolism or thrombotic phenomena related to the cyanoacrylate injection were reported. One patient died of sepsis during an admission 7 months later. Th is death was deemed to be unrelated to the procedure but was included in the analysis.
DISCUSSION
Treating gastric and duodenal variceal bleeding in patients who are deemed to be ineligible for TIPS placement is a challenging therapeutic dilemma for the gastroenterologist; high-risk decompensated patients with cirrhosis have limited options for treatment. Th e fi ndings of our single-center retrospective study confi rm results reported by Rengstorff et al ( 6 ) and Monsanto et al ( 7 ), where the use of cyanoacrylate injection is very eff ective in controlling gastric variceal bleeding with an acceptable safety profi le. Studies from China, Portugal, and the United States have reported rebleeding rates in the range of 4% to 14.4% (6) (7) (8) .
Our patient population consisted of subjects with active gastric variceal bleeding, and we were able to achieve hemostasis in 93% of them. Previous studies have shown cyanoacrylate injection to have better effi cacy than variceal ligation ( 7 ) and results equivalent to those of TIPS ( 9 ) . A minority of patients were referred for glue injection for secondary prophylaxis. No patients in this group developed rebleeding, although we recognize this was a small portion of patients in our study. In addition, our study included 3 patients who underwent injection of duodenal varices with successful hemostasis without subsequent evidence of bleeding.
Complications associated with glue injection include fever, abdominal pain, bacteremia, and thrombotic phenomena such as pulmonary embolism and stroke. Th e rate of complications appears to be mitigated by slowing the infusion rate as well as using a smaller amount of cyanoacrylate. No patients in our study developed procedure-related complications. Th ere was one technical complication related to the deployment of cyanoacrylate, which may be related to the priming of the catheter. Th ere was only one death in our study, which occurred 7 months after the procedure on a separate admission to the hospital, which we did not think was related to endoscopic therapy.
Th e limitations of our study include its retrospective nature and the small size of our patient population. Th e procedures were performed by experienced endoscopists; thus, results may not be generalizable. Although we followed patients for more than 1 year, we cannot guarantee that in our tertiary referral center no patients were lost to follow up. In this particular high-risk population, the use of tissue adhesives should still be considered when options are scarce for decompensated cirrhotics requiring management of gastric variceal bleeding.
